Journal article
Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis
Hemodialysis international, Vol.21(2), pp.243-249
04/2017
DOI: 10.1111/hdi.12487
PMID: 27615161
Abstract
Oral phosphate binders are the main stay of treatment of hyperphosphatemia. Adherence rates to ferric citrate, a recently approved phosphate binder, are unknown.
We conducted a post-hoc analysis to evaluate whether adherence rates were different for ferric citrate vs. active control in 412 subjects with end stage kidney disease (ESKD) who were randomized to ferric citrate vs. active control (sevelamer carbonate and/or calcium acetate). Adherence was defined as percent of actual number of pills taken to total number of pills prescribed.
There were no significant differences in baseline characteristics including gender, race/ethnicity, and age between the ferric citrate and active control groups. Baseline phosphorus, calcium, and parathyroid hormone levels were similar. Mean (SD) adherence was 81.4% (17.4) and 81.7% (15.9) in the ferric citrate and active control groups, respectively (P = 0.88). Adherence remained similar between both groups after adjusting for gender, race/ethnicity, age, cardiovascular disease (CVD), and diabetic nephropathy (mean [95% CI]: 81.4% [78.2, 84.6] and 81.5% [77.7, 85.2] for ferric citrate and active control, respectively). Gender, race/ethnicity, age, and diagnosis of diabetic nephropathy did not influence adherence to the prescribed phosphate binder. Subjects with CVD had lower adherence rates to phosphate binder; this was significant only in the active control group.
Adherence rates to the phosphate binder, ferric citrate, were similar to adherence rates to active control. Similar adherence rates to ferric citrate are notable since tolerance to active control was an entry criteria and the study was open label. Gender, race/ethnicity, nor age influenced adherence.
Details
- Title: Subtitle
- Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis
- Creators
- Diana Jalal - University of Colorado, Aurora, Colorado, USAMolly McFadden - University of Utah, Salt Lake, Utah, USAJamie P Dwyer - Vanderbilt University School of Medicine, Nashville, Tennessee, USAKausik Umanath - Henry Ford Hospital, Detroit, Michigan, USAErwin Aguilar - Louisiana State University Health Center, New Orleans, Louisiana, USAYoram Yagil - Ben-Gurion University of the Negev, Beer Sheba and Barzilai University Medical Center, Ashkelon, IsraelBarbara Greco - Baystate Medical Center, Springfield, Massachusetts, USAMohammed Sika - Vanderbilt University School of Medicine, Nashville, Tennessee, USAJulia B Lewis - Vanderbilt University School of Medicine, Nashville, Tennessee, USATom Greene - University of Utah, Salt Lake, Utah, USASimin Goral - University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Resource Type
- Journal article
- Publication Details
- Hemodialysis international, Vol.21(2), pp.243-249
- DOI
- 10.1111/hdi.12487
- PMID
- 27615161
- NLM abbreviation
- Hemodial Int
- ISSN
- 1492-7535
- eISSN
- 1542-4758
- Language
- English
- Date published
- 04/2017
- Academic Unit
- Nephrology; Internal Medicine
- Record Identifier
- 9984094753002771
Metrics
34 Record Views